StocksMedium•11 November 2026•
1 min read
Immutep Reports Positive Cancer Trial Data and Secures New US Patent
Key Facts
1Immutep reported encouraging survival data from its Phase 2 sarcoma trial evaluating eftilagimod alpha (efti).
2The company secured a key U.S. patent valid through 2038 related to antibody formulations.
Immutep reported encouraging survival data from its Phase 2 sarcoma trial evaluating eftilagimod alpha (efti). Benzinga reported that the company also secured a key U.S. patent related to antibody formulations, which remains valid through 2038.
IMMP closed at $3.46 on November 10, 2026, with the stock reaching a day high of $3.69 and a low of $3.40 during the session. The combination of positive clinical progression and long-term intellectual property protection serves as a catalyst for the biotech firm's pipeline.